GCG and neoplasm: Furthermore, studies have indicated that new glucose-lowering agents, such as glucagon-like peptide-1 (GLP-1) analogues, can offer new strategies and methodologies for tumor immunotherapy by improving NK cell function among other mechanisms (27).